A Study to Evaluate the Efficacy and Tolerability of Dasabuvir and Ombitasvir/Paritaprevir/Ritonavir With or Without Ribavirin in Patients With HIV-HCV Genotype 1 Coinfection

Trial Profile

A Study to Evaluate the Efficacy and Tolerability of Dasabuvir and Ombitasvir/Paritaprevir/Ritonavir With or Without Ribavirin in Patients With HIV-HCV Genotype 1 Coinfection

Completed
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 28 Dec 2016

At a glance

  • Drugs Dasabuvir (Primary) ; Ombitasvir/paritaprevir/ritonavir (Primary) ; Ribavirin
  • Indications Hepatitis C
  • Focus Expanded access; Therapeutic Use
  • Most Recent Events

    • 28 Dec 2016 Status changed from recruiting to completed, according to results published in the Clinical Infectious Diseases.
    • 22 Dec 2016 Results assessing safety and efficacy (n=213) published in the Clinical Infectious Diseases.
    • 12 May 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top